Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 16/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14894844 | 0.86 | GAA (0.64) | GAAPOLBCXCR2CXCR1MAPT | |
| SCHEMBL12914115 | 0.80 | GAA (0.68) | GAAPOLBCXCR2CXCR1MAPT | |
| SCHEMBL20721181 | 0.79 | GAA (0.67) | GAAPOLBCXCR2CXCR1MAPT | |
| SCHEMBL20761208 | 0.79 | GAA (0.60) | GAAPOLBCXCR2CXCR1MAPT | |
| SCHEMBL1707274 | 0.79 | CXCR2 (0.66) | GAACXCR2CXCR1CCR6 | |
| SCHEMBL18310046 | 0.78 | GAA (0.58) | GAAPOLBCXCR2CXCR1MAPT | |
| SCHEMBL12261147 | 0.77 | CXCR2 (0.63) | GAACXCR2CXCR1CCR6 | |
| SCHEMBL14896251 | 0.77 | GAA (0.61) | GAAPOLBCXCR2CXCR1MAPT | |
| SCHEMBL9979964 | 0.77 | GAA (0.64) | GAACXCR2CXCR1MAPT | |
| SCHEMBL20760855 | 0.77 | GAA (0.64) | GAAPOLBCXCR2CXCR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | GAA 3569/4885POLB 2098/4885CXCR2 303/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | GAA 3569/4885POLB 2098/4885CXCR2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.